Pepper, C., Hoy, T. and Bentley, D.P. (1997) BCL-2/Bax Ratios in Chronic Lymphocytic Leukaemia and Their Correlation with in Vitro Apoptosis and Clinical Resistance. British Journal of Cancer, 76, 935-938.
https://doi.org/10.1038/bjc.1997.487

has been cited by the following article:

• TITLE: Prognostic Significance of Apoptosis Regulators in B-Cell Chronic Lymphocytic Leukemia

  AUTHORS: Ahmad Baraka, Shereen El Shorbagy, Ola M. Elfarargy, Rasha Haggag, Lobna A. Abdelaziz, Salah F. Elsayed, Khaled A. Elbana

  KEYWORDS: Myeloid Cell Leukemia 1, B-Cell Lymphoma 2, BAX, B-Cell Chronic Lymphocytic Leukemia

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.4, April 28, 2017

  ABSTRACT: Background: High levels of MCL-1 and BCL-2 proteins have been found in Chronic Lymphocytic Leukemia (CLL), and inversely correlated with response to treatment. BCL-2/Bax ratio is the main director of apoptosis in CLL. The study aimed to clarify the prognostic role of MCL-1, BCL-2 and BCL-2/ Bax ratio in B-CLL. Patients & method: Estimation of MCL-1, BCL-2 and Bax expressions by a flow cytometry in 45 B-CLL patients and the prognostic value of these markers were correlated with other well-known established prognostic markers and treatment response. Results: MCL-1 was expressed in 60% of cases while BCL-2 was expressed in 82.2% of cases. MCL-1 expression was significantly high in male gender, short lymphocyte doubling time (LDT), and high expression of CD 38 (p β2M, CD38 expression), low ZAP-70 expression, splenomegaly and higher Rai stage were significantly increased in patients with high expression of BCL-2 (p β2M, high C-D38 expression, low ZAP-70 expression, the poor cytogenetic and splenomegaly in patients with high expression of BCL-2/ Bax ratio (p In conclusion: MCL-1, BCL-2 expressions and BCL-2/Bax ratio could be useful potential predictive and prognostic markers in B-CLL.